▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / MIRM

MIRM — Mirum Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1759425 ·
Last close
$96.72
Market Cap
$5.90B
52W High
$130.00
52W Low
$88.88
ADV30
666,972
Next earnings
—
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 176,243,000 145,895,000 -26,102,000 -67,227,000 1,044,981,000 330,728,000 1,055,403,000
Mar 2026 159,882,000 131,077,000 -63,163,000 -790,155,000 890,916,000 324,907,000 648,422,000
Dec 2025 148,932,000 120,668,000 -4,567,000 -5,730,000 842,813,000 296,683,000 528,123,000
Sep 2025 133,010,000 107,473,000 2,603,000 2,905,000 785,115,000 282,021,000 493,069,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-227,267,000
Investing CF
$-172,781,000
Financing CF
$506,612,000
CapEx
$-36,474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-14.55
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,524,926,000
Inventory
$25,769,000
Receivables
$145,360,000
ST Investments
$107,563,000
EBIT TTM
$-844,100,000
Pretax Income TTM
$-857,538,000
Interest Exp TTM
$13,438,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$618,067,008
EBITDA
$-70,283,000
Free Cash Flow
$76,618,128
Enterprise Value
$6,578,278,400
Total Cash
$438,291,008
Total Debt
$762,948,992
Shares Out
60,981,227
Trailing EPS
$-14.08
Book Value
$-0.16
ROE
-703.0%
ROA
-6.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 521,312,000 -22,136,000 -23,363,000 842,813,000 528,123,000 — 55,827,000
Dec 2024 336,888,000 -87,606,000 -87,942,000 670,754,000 445,114,000 — 10,325,000
Dec 2023 186,374,000 -109,154,000 -163,415,000 646,621,000 397,951,000 — -70,944,000
Dec 2022 77,062,000 -131,220,000 -135,665,000 352,906,000 210,869,000 — -120,136,000

TTM Snapshot

Revenues TTM
$138,102,000
NetIncome TTM
$-37,823,000
OpCashFlow TTM
$0
Assets (Latest)
$670,754,000
Forward EPS
$-0.35

Max Pain — expiry 2026-12-18

max pain strike: $85.00 · spot: $96.72 · call oi: 1,198 · put oi: 469
Expected Move to 2026-12-18: ±$31.05 (32.10%) — implied range $65.67 – $127.77 · ATM straddle on $95.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PTCT PTC THERAPEUTICS, INC. $5.93B $71.06 —
XENE Xenon Pharmaceuticals Inc. $5.86B $60.56 —
DNTH Dianthus Therapeutics, Inc. /DE/ $6.02B $110.07 —
TVTX Travere Therapeutics, Inc. $6.06B $65.22 —
ERAS Erasca, Inc. $6.16B $17.60 —

News headlines (Yahoo Finance, 1h cache)

Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next
2026-08-13 17:12 · Yahoo
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript
2026-08-12 23:14 · Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-11 20:01 · Yahoo
Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%
2026-08-06 13:46 · Yahoo
Mirum Pharmaceuticals Q2 Earnings Call Highlights
2026-08-06 03:03 · Yahoo
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-05 20:01 · Yahoo
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
2026-07-29 20:01 · Yahoo
The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib
2026-07-02 09:14 · Yahoo
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
2026-06-29 14:52 · Yahoo
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?
2026-06-25 12:41 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →